Adaptive Biotechnologies Corp. (ADPT)

Over the past six months, Adaptive Biotechnologies' stock price has been impacted by its financial performance and insider trading. The stock has seen a significant increase of 92.21% over the past year, with a share price of $14.81 as of April 2, 2026, compared to $7.70 on April 7, 2025, but has experienced some volatility, with a -4.5% change in the past six months. Adaptive Biotechnologies reported strong fourth-quarter and full-year 2025 financial results, with total revenue for the full year 2025 being $277.0 million, a 55% increase year-over-year. The MRD business was a significant driver, contributing 86% of Q4 revenue and achieving positive Adjusted EBITDA and cash flow. The company reported strong third-quarter results, with revenue of $94.0 million, a 102% increase from the prior year. Adaptive Biotechnologies reported a 36% increase in revenue for the second quarter of 2025, reaching $58.9 million. There has been significant insider selling activity, particularly in early 2026. Following the Q4 2025 earnings, BTIG and TD Cowen raised its price target, both maintaining a Buy rating, and Piper Sandler also reiterated an Overweight rating. Analyst sentiment remains largely positive, with an average price target suggesting a 26.89% upside.

For Adaptive Biotechnologies' products and services, particularly its clonoSEQ test, there can be some seasonality. Weather-related impacts on clonoSEQ volume in Q1 have been acknowledged, though samples typically flow back in large volumes, leading to a strong start to Q1. Management expects MRD revenue to be approximately 45% weighted to the first half of the year and 55% to the second half, with sequential clinical volume growth anticipated throughout the year. The company is targeting over 30% clonoSEQ test volume growth in 2026, driven by a shift towards blood-based testing, deeper community penetration, and expanded EMR integration, which could help mitigate seasonal fluctuations.

Adaptive Biotechnologies Corp. is a commercial-stage biotechnology company focused on immune-driven medicine, operating in the Healthcare sector and Biotechnology industry. The company decodes and applies the genetics of the adaptive immune system to transform the diagnosis and treatment of diseases such as cancer, autoimmune conditions, and infectious diseases. Its immune medicine platform uses immunosequencing technology, computational biology, and machine learning to read the genetic code of a patient's immune system. The company's major products and services are categorized into two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The clonoSEQ® Assay is a clinical diagnostic test used to detect and monitor minimal residual disease (MRD) in patients with hematologic malignancies and is the first and only FDA-cleared test for detecting MRD in select blood cancers. The immunoSEQ® Platform profiles T-cell receptor (TCR) and B-cell receptor genes and is used by researchers for discoveries in oncology, autoimmune disorders, infectious diseases, and basic immunology. Adaptive Biotechnologies collaborates with biopharmaceutical companies to inform drug development and discover and develop transformative immune-based therapies for diseases like cancer and autoimmune disorders.

Adaptive Biotechnologies Corp. is headquartered in Seattle, Washington, United States. The company has a global reach with operations in the United States, Europe, and Asia.

Adaptive Biotechnologies' brand reputation appears to be largely positive, driven by strong financial performance and advancements in its core business. The company has reported accelerating MRD revenue growth, rising clonoSEQ volumes, and improving Adjusted EBITDA. Consistently beating analyst expectations for earnings and revenue, especially in its MRD business, has positively impacted its reputation among investors and analysts. Receiving expanded Medicare coverage for clonoSEQ for recurrence monitoring in mantle cell lymphoma is a significant positive development, reinforcing the clinical utility and acceptance of its diagnostic test. The launch of clonoSEQ integration into Flatiron's OncoEMR and the implementation of NovaSeq X Plus for clonoSEQ clinical sequencing demonstrate the company's commitment to innovation and broader adoption of its technologies. Signing immune-receptor data licenses with major pharmaceutical companies like Pfizer further validates the value of Adaptive's immune medicine platform and its potential for drug discovery. The consensus among analysts is a "Moderate Buy," with price targets suggesting significant upside, indicating a positive outlook on the company's future prospects.

Adaptive Biotechnologies Corporation has a significant institutional ownership, with 284 institutional owners holding a total of 150,118,349 shares as of April 9, 2026, accounting for approximately 89.1% of the company, while individuals hold about 3.94%. Major institutional owners include Viking Global Investors Lp, BlackRock, Inc., Vanguard Group Inc, Price T Rowe Associates Inc /md/, Westfield Capital Management Co Lp, Geode Capital Management, Llc, State Street Corp, Invesco Ltd., Lord, Abbett & Co. Llc, and Goldman Sachs Group Inc. Andreas Halvorsen is noted as owning the most shares of Adaptive Biotechnologies Corp among individual owners.